This is a prospective observational cohort study designed to collect data on patients who received REBYOTAâ„¢ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTAâ„¢ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTAâ„¢ administration.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of patients without Recurrence of Clostridioides Difficile Infection (rCDI) (as determined by the treating physician)
Timeframe: 8 weeks after initial REBYOTAâ„¢ treatment